04:29 PM EDT, 09/25/2025 (MT Newswires) -- Cidara Therapeutics ( CDTX ) said it has dosed the first participants in its Phase 3 anchor trial testing CD388, a non-vaccine preventative for seasonal influenza in high-risk populations.

The study, which is expected to enroll 6,000 participants globally beginning with the Northern Hemisphere flu season, will include adults over 65 as well as people with comorbidities and compromised immune systems. CD388 is administered as a one-time 450-milligram subcutaneous injection.

Cidara said the trial will include an interim analysis after the Northern Hemisphere flu season to determine enrollment for the Southern Hemisphere. If successful, the single Phase 3 trial is expected to be sufficient to support a potential biologics license application submission.

The company reported it had over $500 million in cash at the end of Q2 to fund the program through completion.

Cidara stock fell 4.3% at Thursday's close, with volume of 1.19 million shares compared with a 731,000 average.